LaparoscopyROBOCOSTESNCT04861974
Robotic vs Laparoscopic Study. Spanish Cost Effective Snapshot Study
An observational study of Laparoscopy and Robotic, run by Hospital del Mar.
Trial summary
this is a prospective no randomized study of cost effectiveness of laparoscopic vs robotic study of Distal pancreatectomy, Hernioplasty for inguinal hernia and Rectal resection Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Laparoscopy, Robotic
- How many people
- 180 participants
- Where
- No sites listed yet
- Study dates
- 15 Jun 2021to 15 Jun 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Elective surgery with indication of distal Pancreatectomy , Gastrectomy, Hernioplasty, Rectal resection and Nissen
Who may be able to join
- Elective surgery with indication of distal Pancreatectomy , Gastrectomy, Hernioplasty, Rectal resection and Nissen performed by laparoscopy or robotic
- >18 years old
Who cannot join
- Patients who do not want to participate
- Previous abdominal surgeries
About this study
Official title: Estudio Coste-Efectividad "Snapshot" Nacional de Costes robótica vs laparoscópica
this is a prospective no randomized study of cost effectiveness of laparoscopic vs robotic study of Distal pancreatectomy, Hernioplasty for inguinal hernia and Rectal resection
Read the detailed description
Robotic is having increased interest in the last decade and on of its limits is the cost.
From previous report Robotic surgery entails higher costs. However, cost solely is not enough to validate a new procedure. Whenever a new technology is introduced it is important to evaluate cost and improved quality of life as well, which is the Cost Effectiveness (CE) study.
The aim of our study is to evaluate in Spain the CE of laparoscopic and robotic procedure of Distal Pancreatectomy, Gastrectomy, Nissen procedure, Rectal resection and Inguinal hernia repair.
This is a prospective snapshot study during 6 months in which patients are included from several Spanish centers. Cost are defined according to the spain official cost data recorded from the RECH (https://www.rechosp.org).
Main clinical outcomes are gathered divided in intra operative and post operative data.
Quality of life (EQ 5D-5L) is recorded as well pre operatively and post operatively at 30 days and 9 days from the surgery, time in which the follow up is ended.
A cost effectiveness analysis is finally performed:
A model-based cost-utility analysis estimating mean costs and QALYs per patient was performed.
The Institute for Validation of Clinical Efficacy (IVEC) of the HM Hospitals group was responsible for capturing costs ascribed to each patient's treatment. The total direct hospital costs of care, with the exception of the acquisition or maintenance of the robotic device.
Materials and medicines used during surgery were standardized so that the same materials were used in all patients undergoing surgery regardless of the technique employed (Robotic or Laparoscopic). Operative costs included the cost of the operating room in relation to the operative time, and all required supplies (including all laparoscopic devices, sutures, and instruments), anaesthesia, laboratory and related blood transfusion costs when required. Hospitalization costs included costs associated with room and board, the length of hospital stay (including intensive care, medications, blood transfusion, parenteral nutrition and radiology charge) and costs for surgical visits (programmed and emergency) as well as readmission costs up to 90 days from surgery. The direct costs of the professionals involved have not been calculated as they did not vary between the two types of operation. A discount rate of 3% per year is used in the estimation of the costs and QALYs, as recommended by health economic guidelines (9) All costs are presented in Euros (exchange rate 2021).
Stochastic cost-utility analysis was undertaken, whereby the incremental cost-effectiveness ratio (ICER) was estimated using overall costs of the RRR and LRR procedures and QALYs derived from patient interviews, in order to find the incremental cost per QALYs gained.
Net monetary benefits (NMBs) were calculated in order to estimate the maximum willingness to pay (WTP) of decision makers for a QALY gained. The NMB was calculated as the mean QALYs per patient multiplied by WTP threshold minus the mean cost per patient for the treatment. The decision rule is to adopt the treatment if the NMB > 0, and the alternative with the highest NMB represents best value for money.
Sensitivity analysis A sensitivity analysis was carried out in order to propagate the uncertainty of the estimations to the results of the model. We used a multivariate and stochastic sensitivity analysis performed by 5,000 Monte Carlo simulations. The cost-effectiveness plane was used to represent all pairs of solutions of the model.
The results of the one-way sensitivity analysis are shown in the tornado diagram which depicts graphically how variations in each input affect the outcome. The 95% confidence intervals around the base case values were derived using the 2.5 and 97.5 percentiles calculated from the sensitivity analysis.
The tornado diagram is stacked in order of decreasing width, indicating that variations in inputs near the top (Total Costs Robotic) have the greatest effect on the outcome, while variations in inputs near the bottom (QALYs discount rate) have relatively small effects on the outcome.
Acceptability curve The investigators also computed a cost-effectiveness acceptability curve which plots the probability that the Robotic was cost-effective relative to Laparoscopy over a reasonable range of levels of willingness-to-pay.
Although in Spain there is no specific willing to pay threshold in healthcare, according to the National Institute for Health Care Excellence (NICE), the investigators used a willingness-to-pay of 20,000 € and 30,000 € per QALY as a threshold to recognize which treatment was most cost-effective
Statistics Data have been recorded in a SPSS Statistics Version 20.0 database and are expressed as median values (interquartile range-IQR 25-75). Categorical data are presented as numbers (%). To compare the means of the quantitative variables when the variables followed a normal distribution, a variance analysis and a Student's t-test were used. For the rest of the variables, both Mann-Whitney and Kruskal-Wallis tests were performed. Cost, QALYs and incremental results are presented in a 95% Confidence Interval. A p value < .05 was considered significant. Data herein reported are for patients who reached a minimum of one year of follow up.
- Conditions
- Laparoscopy, Robotic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Robotic Distal Pancreatectomy | Not described | |
| Laparoscopic Distal Pancreatectomy | Not described | |
| Robotic Gastrectomy | Not described | |
| Laparoscopic Gastrectomy | Not described | |
| Robotic Funduplication | Not described | |
| Laparoscopic Funduplication | Not described | |
| Robotic Hernioplasty | Not described | |
| Laparoscopic Hernioplasty | Not described | |
| Robotic Rectal Resection | Not described | |
| Laparoscopic Rectal Resection | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cost Effectiveness
This is the increased cost differences of the new technology to improve the quality of life after the intervention
Measured: 90 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Apr 2021
- Study start15 Jun 2021 (estimated)
- Primary completion15 Apr 2022 (estimated)
- Study completion15 Jun 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for LaparoscopyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 180 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hospital del Mar
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Benedetto Ielpo, Hospital del Mar
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04861974
- Sponsor's protocol ID
- Robocostes
- Acronym
- ROBOCOSTES
- Status last verified
- Apr 2021
- First submitted
- 21 Apr 2021
- Last updated
- 27 Apr 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Apr 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Estudio Coste-Efectividad "Snapshot" Nacional de Costes robótica vs laparoscópica
- ClinicalTrials.gov ID
- NCT04861974
- Acronym / sponsor ID
- ROBOCOSTES / Robocostes
- Conditions
- Laparoscopy, Robotic
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 180 participants (estimated)
- Lead sponsor
- Hospital del MarUniversity, hospital or other
- Study start
- 15 Jun 2021 (estimated)
- Primary completion
- 15 Apr 2022 (estimated)
- Study completion
- 15 Jun 2022 (estimated)
- First posted
- 27 Apr 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
this is a prospective no randomized study of cost effectiveness of laparoscopic vs robotic study of Distal pancreatectomy, Hernioplasty for inguinal hernia and Rectal resection
Detailed description
Robotic is having increased interest in the last decade and on of its limits is the cost.
From previous report Robotic surgery entails higher costs. However, cost solely is not enough to validate a new procedure. Whenever a new technology is introduced it is important to evaluate cost and improved quality of life as well, which is the Cost Effectiveness (CE) study.
The aim of our study is to evaluate in Spain the CE of laparoscopic and robotic procedure of Distal Pancreatectomy, Gastrectomy, Nissen procedure, Rectal resection and Inguinal hernia repair.
This is a prospective snapshot study during 6 months in which patients are included from several Spanish centers. Cost are defined according to the spain official cost data recorded from the RECH (https://www.rechosp.org).
Main clinical outcomes are gathered divided in intra operative and post operative data.
Quality of life (EQ 5D-5L) is recorded as well pre operatively and post operatively at 30 days and 9 days from the surgery, time in which the follow up is ended.
A cost effectiveness analysis is finally performed:
A model-based cost-utility analysis estimating mean costs and QALYs per patient was performed.
The Institute for Validation of Clinical Efficacy (IVEC) of the HM Hospitals group was responsible for capturing costs ascribed to each patient's treatment. The total direct hospital costs of care, with the exception of the acquisition or maintenance of the robotic device.
Materials and medicines used during surgery were standardized so that the same materials were used in all patients undergoing surgery regardless of the technique employed (Robotic or Laparoscopic). Operative costs included the cost of the operating room in relation to the operative time, and all required supplies (including all laparoscopic devices, sutures, and instruments), anaesthesia, laboratory and related blood transfusion costs when required. Hospitalization costs included costs associated with room and board, the length of hospital stay (including intensive care, medications, blood transfusion, parenteral nutrition and radiology charge) and costs for surgical visits (programmed and emergency) as well as readmission costs up to 90 days from surgery. The direct costs of the professionals involved have not been calculated as they did not vary between the two types of operation. A discount rate of 3% per year is used in the estimation of the costs and QALYs, as recommended by health economic guidelines (9) All costs are presented in Euros (exchange rate 2021).
Stochastic cost-utility analysis was undertaken, whereby the incremental cost-effectiveness ratio (ICER) was estimated using overall costs of the RRR and LRR procedures and QALYs derived from patient interviews, in order to find the incremental cost per QALYs gained.
Net monetary benefits (NMBs) were calculated in order to estimate the maximum willingness to pay (WTP) of decision makers for a QALY gained. The NMB was calculated as the mean QALYs per patient multiplied by WTP threshold minus the mean cost per patient for the treatment. The decision rule is to adopt the treatment if the NMB > 0, and the alternative with the highest NMB represents best value for money.
Sensitivity analysis A sensitivity analysis was carried out in order to propagate the uncertainty of the estimations to the results of the model. We used a multivariate and stochastic sensitivity analysis performed by 5,000 Monte Carlo simulations. The cost-effectiveness plane was used to represent all pairs of solutions of the model.
The results of the one-way sensitivity analysis are shown in the tornado diagram which depicts graphically how variations in each input affect the outcome. The 95% confidence intervals around the base case values were derived using the 2.5 and 97.5 percentiles calculated from the sensitivity analysis.
The tornado diagram is stacked in order of decreasing width, indicating that variations in inputs near the top (Total Costs Robotic) have the greatest effect on the outcome, while variations in inputs near the bottom (QALYs discount rate) have relatively small effects on the outcome.
Acceptability curve The investigators also computed a cost-effectiveness acceptability curve which plots the probability that the Robotic was cost-effective relative to Laparoscopy over a reasonable range of levels of willingness-to-pay.
Although in Spain there is no specific willing to pay threshold in healthcare, according to the National Institute for Health Care Excellence (NICE), the investigators used a willingness-to-pay of 20,000 € and 30,000 € per QALY as a threshold to recognize which treatment was most cost-effective
Statistics Data have been recorded in a SPSS Statistics Version 20.0 database and are expressed as median values (interquartile range-IQR 25-75). Categorical data are presented as numbers (%). To compare the means of the quantitative variables when the variables followed a normal distribution, a variance analysis and a Student's t-test were used. For the rest of the variables, both Mann-Whitney and Kruskal-Wallis tests were performed. Cost, QALYs and incremental results are presented in a 95% Confidence Interval. A p value < .05 was considered significant. Data herein reported are for patients who reached a minimum of one year of follow up.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 10
| Arm | Type | Receives |
|---|---|---|
| Robotic Distal Pancreatectomy | – | – |
| Laparoscopic Distal Pancreatectomy | – | – |
| Robotic Gastrectomy | – | – |
| Laparoscopic Gastrectomy | – | – |
| Robotic Funduplication | – | – |
| Laparoscopic Funduplication | – | – |
| Robotic Hernioplasty | – | – |
| Laparoscopic Hernioplasty | – | – |
| Robotic Rectal Resection | – | – |
| Laparoscopic Rectal Resection | – | – |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Elective surgery with indication of distal Pancreatectomy , Gastrectomy, Hernioplasty, Rectal resection and Nissen
Key inclusion criteria (2 listed)
- Elective surgery with indication of distal Pancreatectomy , Gastrectomy, Hernioplasty, Rectal resection and Nissen performed by laparoscopy or robotic
- >18 years old
Key exclusion criteria (2 listed)
- Patients who do not want to participate
- Previous abdominal surgeries
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Cost Effectiveness
Time frame: 90 days
This is the increased cost differences of the new technology to improve the quality of life after the intervention
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Apr 2021.
Related trials for Laparoscopy
Not yet recruiting
Two Bupivacaine Concentrations for Recto-Intercostal Fascial Plane Block After Laparoscopic Cholecystectomy
Postoperative Pain, Acute Pain
Enrolling by invitationObservational study
Intestinal Obstruction Surgery. Acute Abdominal Pathology. №9:05/05/2026
Small Bowel Adhesion, Obstruction Bowel
Not yet recruiting
Generative AI-Assisted Personalized Feedback for Laparoscopic Skill Learning in Medical Undergraduates
Medical Education
RecruitingObservational study
Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults With Obesity
Obesity & Overweight
Active, not recruiting
Evaluating the Efficacy and Safety of a New Laparoscopic Non-mesh Hernia Needle Set Designed for Indirect Inguinal Hernia
Inguinal Hernia, Without Mention of Obstruction or Gangrene
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Laparoscopy and Robotic, run by Hospital del Mar.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 27 Apr 2021. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cost Effectiveness (time frame: 90 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Apr 2021.